Gene info: ID 27436

Gene: EML4

GENE ID: 27436

Synonyms: C2orf2|ELP120|EMAP-4|EMAPL4|ROPP120

Description: echinoderm microtubule associated protein like 4

Gene type: protein-coding

Location: 2p21

dbXrefs: Ensembl:ENSG00000143924 MIM:607442 Vega:OTTHUMG00000128603 UniprotKB:Q9HC35

RefSeq: NC_000002.12

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 62

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 4.370e-1 (AD) 5.142e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
PTBP3	0.869
GNS	0.849
SLC30A7	0.845
ANKHD1	0.841
ZNF700	0.837
BTAF1	0.835
NCOA3	0.833
FKBP15	0.83
NUP205	0.828
TMEM87B	0.825

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.457
OR4F29	-0.432
HES6	-0.235
PLA2G5	-0.23
APOA1	-0.213
DIAPH3	-0.211
HPR	-0.21
S100A1	-0.208
HES5	-0.203
NXNL1	-0.198

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C448659	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin results in decreased stability of EML4 protein mutant form	22912387
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EML4 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EML4 mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EML4 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EML4 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EML4 mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EML4 mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased expression of EML4 mRNA	21420995
D000082	Acetaminophen	Acetaminophen affects the expression of EML4 mRNA	17562736
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of EML4 gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of EML4 mRNA	23630614
D000393	Air Pollutants	Air Pollutants analog results in decreased expression of EML4 mRNA	21757418
C025154	alpha-cobratoxin	alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]	12588870
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of EML4 mRNA	24449571
C006632	arsenic trioxide	arsenic trioxide results in increased expression of EML4 protein	25419056
D001554	Benzene	Benzene results in increased expression of EML4 mRNA	19162166
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of EML4 mRNA	26001963
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of EML4 mRNA	20064835\|2010694
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of EML4 mRNA"	19150397\|2001819
C006780	bisphenol A	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EML4 mRNA	28628672
C006780	bisphenol A	bisphenol A results in decreased expression of EML4 mRNA	25181051
D020122	tert-Butylhydroperoxide	tert-Butylhydroperoxide results in decreased expression of EML4 mRNA	15336504
C018475	butyraldehyde	butyraldehyde results in decreased expression of EML4 mRNA	26079696
D019256	Cadmium Chloride	Cadmium Chloride results in decreased methylation of EML4 promoter	22457795
D002737	Chloroprene	Chloroprene results in increased expression of EML4 mRNA	23125180
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of EML4 mRNA	24386269
D019327	Copper Sulfate	Copper Sulfate results in increased expression of EML4 mRNA	19549813
C551994	crizotinib	crizotinib results in decreased stability of EML4 protein mutant form	22912387
C551994	crizotinib	crizotinib results in increased mutagenesis of EML4 gene mutant form	21502504
C551994	crizotinib	[crizotinib results in increased mutagenesis of EML4 gene mutant form] which results in decreased susceptibility to crizotinib	21502504
C029892	cupric chloride	cupric chloride results in decreased expression of EML4 mRNA	17211630
D016572	Cyclosporine	Cyclosporine results in decreased expression of EML4 mRNA	20106945\|2556210
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EML4 mRNA	28628672
D004237	Diuron	Diuron results in decreased expression of EML4 mRNA	25152437
D004791	Enzyme Inhibitors	[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of EML4 protein	23301498
C045651	epigallocatechin gallate	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EML4 mRNA	22079256
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of EML4 mRNA	21179406
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EML4 mRNA	28628672
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of EML4 mRNA	25613284
C051890	irinotecan	irinotecan affects the expression of EML4 mRNA	20097248
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of EML4 mRNA	28628672
C008261	lead acetate	[lead acetate co-treated with zinc protoporphyrin] results in increased expression of EML4 mRNA	22839698
C045463	leflunomide	leflunomide results in increased expression of EML4 mRNA	24136188
D008464	Mecamylamine	Mecamylamine promotes the reaction [Nicotine results in decreased expression of EML4 mRNA]	12588870
D008464	Mecamylamine	Mecamylamine results in decreased expression of EML4 mRNA	12588870
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of EML4 mRNA	23103053
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of EML4 mRNA	28001369
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of EML4 mRNA"	26251327
C051752	nefazodone	nefazodone results in decreased expression of EML4 mRNA	24136188
D009532	Nickel	Nickel results in increased expression of EML4 mRNA	24768652
D009538	Nicotine	alpha-cobratoxin inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]	12588870
D009538	Nicotine	Mecamylamine promotes the reaction [Nicotine results in decreased expression of EML4 mRNA]	12588870
D009538	Nicotine	Nicotine results in decreased expression of EML4 mRNA	12588870
D009538	Nicotine	Tubocurarine inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]	12588870
C012655	nimesulide	nimesulide results in decreased expression of EML4 mRNA	24136188
C025589	ochratoxin A	ochratoxin A results in decreased expression of EML4 mRNA	19287073
C030110	oxaliplatin	[oxaliplatin co-treated with Topotecan] results in decreased expression of EML4 mRNA	25729387
D010634	Phenobarbital	Phenobarbital results in decreased expression of EML4 mRNA	19270015
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EML4 mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of EML4 mRNA	26272509
C027373	potassium chromate(VI)	[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of EML4 mRNA	22079256
C027373	potassium chromate(VI)	potassium chromate(VI) results in decreased expression of EML4 mRNA	22079256
C089730	rosiglitazone	rosiglitazone results in increased expression of EML4 mRNA	16982809
D012402	Rotenone	Rotenone results in increased expression of EML4 mRNA	27979718
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of EML4 mRNA	25895662
C017947	sodium arsenite	sodium arsenite results in decreased methylation of EML4 gene	25199682
C017947	sodium arsenite	sodium arsenite results in increased stability of EML4 mRNA	25493608
C020806	tetrabromobisphenol A	tetrabromobisphenol A results in decreased expression of EML4 mRNA	27914987
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of EML4 mRNA	20106945\|2163298
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of EML4 mRNA	21570461\|2637764
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin binds to AHR protein] which results in increased expression of EML4 mRNA	16214954
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in increased expression of EML4 mRNA	25975270
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of EML4 mRNA	18796159\|2188995
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of EML4 mRNA	18796159\|2121527
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of EML4 mRNA	25613284
D019772	Topotecan	[oxaliplatin co-treated with Topotecan] results in decreased expression of EML4 mRNA	25729387
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EML4 mRNA"	27188386
C012589	trichostatin A	trichostatin A results in increased expression of EML4 mRNA	24935251\|2627250
C012589	trichostatin A	trichostatin A results in increased expression of EML4 mRNA	15901671
D014403	Tubocurarine	Tubocurarine inhibits the reaction [Nicotine results in decreased expression of EML4 mRNA]	12588870
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EML4 mRNA"	27188386
D014635	Valproic Acid	Valproic Acid results in increased expression of EML4 mRNA	23179753\|2438349
D014635	Valproic Acid	Valproic Acid results in increased expression of EML4 mRNA	15901671
D001335	Vehicle Emissions	Vehicle Emissions results in decreased methylation of EML4 gene	25560391
C025643	vinclozolin	vinclozolin affects the expression of EML4 mRNA	19015723\|2303416
C017803	zinc protoporphyrin	[lead acetate co-treated with zinc protoporphyrin] results in increased expression of EML4 mRNA	22839698
C088658	zoledronic acid	zoledronic acid results in increased expression of EML4 mRNA	20977926

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0003674	molecular_function	-	ND	-
GO:0008017	microtubule binding	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000226	microtubule cytoskeleton organization	-	IBA	21873635
GO:0000278	mitotic cell cycle	-	NAS	10995578
GO:0007017	microtubule-based process	-	NAS	10995578

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005737	cytoplasm	-	NAS	10995578
GO:0005874	microtubule	-	IEA	-
GO:0015630	microtubule cytoskeleton	-	IBA	21873635
GO:0016020	membrane	-	HDA	19946888

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
26208325	Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations. (2015)	Chatziandreou I	PLoS One
26788139	EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer. (2015 Dec)	Ren W	Oncol Lett
19667264	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009 Sep 10)	Shaw AT	J Clin Oncol
22707299	Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. (2012 Nov)	Ren S	Cell Biochem Biophys
21562939	Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features. (2011 Aug)	Yano T	Int J Clin Oncol
28103968	[Gene Expression and Clinical Characteristics of Molecular Targeted Therapy in Non-small Cell Lung Cancer Patients in Shandong]. (2017 Jan 20)	Qiao X	Zhongguo Fei Ai Za Zhi
25588859	Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. (2015 May 26)	Campos-Gomez S	Int J Biol Markers
29199691	New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. (2017 Jan-Mar)	Dubey AP	Indian J Cancer
23856136	[Prognosis related clinical and molecular factors in malignant pleural mesothelioma]. (2013 Mar)	Wang YY	Zhonghua Jie He He Hu Xi Za Zhi
26775573	[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)]. (2016 Jan)	Hamard C	Ann Pathol
25360721	Clinicopathologic features of patients with non-small cell lung cancer harboring the EML4-ALK fusion gene: a meta-analysis. (2014)	Wang Y	PLoS One
27103824	Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. (2016)	Wen M	Onco Targets Ther
27330767	Anaplastic lymphoma kinase-positive squamous cell carcinoma of the lung: A case report. (2016 Jul)	Yamamoto Y	Mol Clin Oncol
22483782	Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. (2012 Aug)	Fukui T	Lung Cancer
25407901	Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. (2014 Nov 18)	Guo Y	BMC Cancer
21178715	Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion. (2011 Jan)	Laack E	J Thorac Oncol
18166835	EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. (2008 Jan)	Inamura K	J Thorac Oncol
29610932	EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib. (2018 May)	Huang T	Cancer Chemother Pharmacol
22464348	Lung cancer in never smokers--a review. (2012 Jun)	Couraud S	Eur J Cancer
25582278	EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. (2015 Mar)	Yang Y	Lung Cancer
25789627	Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan. (2015)	Hsu KH	PLoS One
24346098	Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation. (2014 Jan)	Tufman AL	J Thorac Oncol
28534101	Evaluation of ALK gene rearrangement in central nervous system metastases of non-small-cell lung cancer using two-step RT-PCR technique. (2017 Dec)	Nicos M	Clin Transl Oncol
26767032	Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma. (2014 Sep)	Zhu J	Thorac Cancer
26739511	Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening. (2016 Jan 7)	Yang Y	Sci Rep
26200269	Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. (2015 Aug)	Shim HS	J Thorac Oncol
25773866	Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. (2015 May)	Tsai TH	Lung Cancer
22317764	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. (2012 Apr 1)	Zhang Y	Clin Cancer Res
25706305	Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis. (2015)	Zhao F	PLoS One
23052178	EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis. (2012 Jul-Aug)	Lazarev I	Tumori
23664446	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report. (2013 Aug)	Ali G	Lung Cancer
27438512	Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer. (2018 Apr)	Jia X	Appl Immunohistochem Mol Morphol
19234440	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. (2009 Apr)	Inamura K	Mod Pathol
23723294	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). (2013 Sep)	Dearden S	Ann Oncol
28373815	Systemic treatment of non-small cell lung cancer brain metastases. (2016)	Cedrych I	Contemp Oncol (Pozn)
26893860	Genetic alterations in lung adenocarcinoma with a micropapillary component. (2016 Feb)	Furukawa M	Mol Clin Oncol
23928533	[Detection of EML4-ALK fusion gene in non-small cell lung cancer and its clinicopathologic correlation]. (2013 Apr)	Zhong S	Zhonghua Bing Li Xue Za Zhi
24589437	Prospective screening for ALK: clinical features and outcome according to ALK status. (2014 May)	Fallet V	Eur J Cancer
27987580	Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. (2016 Dec)	Chapman AM	Lung Cancer
21420271	[Lung cancer in never smoker: Epidemiology, molecular profiles and treatment]. (2011 Apr)	Hadoux J	Presse Med
26392858	ALK-rearranged squamous cell carcinoma of the lung. (2015 Sep)	Takanashi Y	Respirol Case Rep
22980554	[Cavitating nodules in a 40-year-old non-smoking woman: a very particular tumour]. (2012 Sep)	Albahary MV	Rev Mal Respir
24729716	Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. (2014)	Li H	Onco Targets Ther
23802852	Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients. (2014 Mar)	McQuitty E	Arch Pathol Lab Med
27033383	[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer]. (2016 Apr 8)	Chen LF	Zhonghua Bing Li Xue Za Zhi
22768234	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. (2012)	An SJ	PLoS One
18242762	EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. (2008 Aug)	Shinmura K	Lung Cancer
20926401	EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. (2010 Oct 15)	Sakairi Y	Clin Cancer Res
29661733	Analysis of EML4-ALK rearrangement in non-small cell lung cancer in Argentina. (2018 Feb 26)	Verzura M	Ann Diagn Pathol
24755712	Evidence that the lung Adenocarcinoma EML4-ALK fusion gene is not caused by exposure to secondhand tobacco smoke during childhood. (2014 Jul)	Ryan BM	Cancer Epidemiol Biomarkers Prev
23439505	Silenced expression of NFKBIA in lung adenocarcinoma patients with a never-smoking history. (2013)	Furukawa M	Acta Med Okayama
29123416	Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer. (2017)	Tufman A	Onco Targets Ther
22736493	Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations. (2012 Oct)	Shaozhang Z	Genes Chromosomes Cancer
23919423	Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients. (2013 Oct)	Xia N	Exp Lung Res
20130484	Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. (2010 Apr)	Ou SH	J Thorac Oncol
23341890	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. (2013)	Li Y	PLoS One
25434695	A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population. (2014 Dec 1)	Hong S	Sci Rep
23098378	Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. (2013 Jan)	Li H	Lung Cancer
27943404	The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. (2017 May)	Skov BG	Histopathology
24388371	Effective enrichment strategy for EML4-ALK fusion gene screening in patients with non-small cell lung cancer. (2014 Jan)	Kobayashi M	Respir Investig
20659620	Recurrent EML4-ALK-associated lung adenocarcinoma with a slow clinical course. (2010 Sep)	Murakami S	Lung Cancer
25180059	Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples. (2014 Jun)	Zhao C	Transl Oncol